Anika Therapeutics(US:ANIK) Globenewswire·2026-01-08 12:00Core Viewpoint - Anika Therapeutics has announced a leadership transition, appointing Stephen Griffin as the new President and CEO, effective February 1, 2026, succeeding Cheryl R. Blanchard, who will become Executive Chair of the Board of Directors [1][5]. Leadership Transition - Stephen Griffin has been with Anika as CFO since 2024 and COO since April 2025, bringing a strong background in strategic transformation and operational excellence [2][6]. - Cheryl R. Blanchard has served as CEO for six years and will continue to support the company as Executive Chair, focusing on regulatory expertise and product development [3][4]. Strategic Focus - Griffin aims to accelerate growth, improve operational discipline and profitability, and direct resources effectively to enhance value for patients, employees, healthcare professionals, and shareholders [3][4]. - Under Blanchard's leadership, Anika has focused on hyaluronic acid innovations, achieving double-digit growth in its commercial channel and launching new products like the Integrity Implant System [3][4]. Board Changes - John B. Henneman, III has been appointed as Lead Independent Director, and the company will accept the resignation of Susan N. Vogt, effective February 1, 2026, due to board size limitations [1][4]. Financial Guidance - Anika has reaffirmed its fiscal 2025 guidance, which was previously confirmed on November 5, 2025, alongside its third-quarter financial results [4].